keyword
MENU ▼
Read by QxMD icon Read
search

paclitaxel AND docetaxel AND gemcitabine AND "non-small cell lung cancer"

keyword
https://www.readbyqxmd.com/read/27867559/impact-of-anticancer-drugs-price-cut-on-physician-s-prescription-choices-on-first-line-chemotherapy-regimens-and-health-expenditure-for-advanced-non-small-cell-lung-cancer-in-china
#1
Bei Li, Mei-Ying Li, Luan-Luan Sun, Jian Wang, Yan-Qing Zheng, Jing Hao
BACKGROUND: Increases in insurance coverage and price cut of drugs are two important measures to make health care more accessible and affordable. As far as we know, this was the first study to explore the impact of anticancer drug price cut on health expenses and oncologist's prescription decisions in China. METHODS: The 511 non-small cell lung cancer (NSCLC) patients were recruited from Qilu Affiliated Hospital of Shandong University from January 1, 2003 to December 31, 2010...
October 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27765756/safety-and-efficacy-of-nivolumab-and-standard-chemotherapy-drug-combination-in-patients-with-advanced-non-small-cell-lung-cancer-a-four-arms-phase-ib-study
#2
S Kanda, K Goto, H Shiraishi, E Kubo, A Tanaka, H Utsumi, K Sunami, S Kitazono, H Mizugaki, H Horinouchi, Y Fujiwara, H Nokihara, N Yamamoto, H Hozumi, T Tamura
BACKGROUND: The human IgG4 monoclonal antibody nivolumab targets programmed cell death-1 (PD-1) and promotes antitumor response by blocking the interaction of PD-1 with its ligands. This single-center phase Ib study investigated the tolerability, safety, and pharmacokinetics of nivolumab combined with standard chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients who had stage IIIB without indication for definitive radiotherapy, stage IV, or recurrent NSCLC were eligible...
October 20, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27266233/quality-of-life-achieved-by-carboplatin-plus-etoposide-as-third-line-chemotherapy-compared-with-best-supportive-care-in-non-small-cell-lung-cancer-stage-iiib-iv
#3
COMPARATIVE STUDY
Jedzada Maneechawakajorn, Sitthichok Hathaisanguan
BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. New third-line chemotherapy drugs including new targeted therapies are expensive and bring about only slightly prolonged progression-free survival and minimally better response in healthy patients...
February 2016: Journal of the Medical Association of Thailand, Chotmaihet Thangphaet
https://www.readbyqxmd.com/read/27217784/real-world-hospital-costs-for-nonchemotherapy-drugs-and-nondrug-care-associated-with-platinum-based-doublets-in-the-first-line-setting-for-advanced-nonsquamous-non-small-cell-lung-cancer-in-chinese-patients-a-retrospective-cohort-study
#4
Jianhua Chen, Shengqi Wu, Chenping Hu, Yicheng Yang, Narayan Rajan, Yun Chen, Canjuan Yang, Jianfeng Li, Wendong Chen
OBJECTIVE: The objective of this study was to compare hospital costs per treatment cycle (HCTC) for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer (AdvNS-NSCLC) in Chinese patients. METHODS: Patients receiving platinum-based doublets in the first-line setting for AdvNS-NSCLC from 2010 to 2012 in two Chinese tertiary hospitals were identified to create the retrospective study cohort...
2016: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27143931/oral-vinorelbine-a-feasible-and-safe-partner-for-radiotherapy-in-the-treatment-of-locally-advanced-non-small-cell-lung-cancer
#5
REVIEW
Francesco Perri, Grazia Lazzari, Giuseppina Della Vittoria Scarpati, Giovanni Silvano
BACKGROUND: Concurrent chemoradiotherapy (CCRT) using cisplatin-based doublets represents the standard of care for locally advanced non-small cell lung cancer (NSCLC), having shown good efficacy and activity in clinical trials. Locally advanced NSCLC occurs frequently in the elderly population, which is often excluded by platinum-based CCRT administration, due to severe associated toxicities. This limitation has been overcome using new-generation drugs such as gemcitabine, docetaxel, paclitaxel, and vinorelbine, which have shown not only to be efficacious but also to have a favorable toxicity spectrum, both in association with cisplatin and as single agents...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/26211584/molecular-docking-of-chemotherapeutic-agents-to-cyp3a4-in-non-small-cell-lung-cancer
#6
Syed Subhani, Kaiser Jamil
CYP3A4, a "heme" containing isoform, abundantly found in the liver, gastro-intestinal tract, lungs and renal cells, also known as drug metabolising enzyme (DME) may be responsible for the disease progression in cancers such as lung cancer. Hence, we have targeted this protein for improving drug selection and in preventing adverse reactions. The aim of this study was to examine chemotherapeutic drug binding to CYP3A4 and the interactions therein. We have used Schrödinger suite 2014, to perform molecular docking of human CYP3A4, by Induced Fit Docking using gemcitabine, cisplatin, carboplatin, docetaxel and paclitaxel drugs...
July 2015: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/25960213/homology-modelling-and-molecular-docking-of-mdr1-with-chemotherapeutic-agents-in-non-small-cell-lung-cancer
#7
Syed Subhani, Archana Jayaraman, Kaiser Jamil
MDR1, a protein commonly involved in drug transport, has been linked to multi drug resistance and disease progression in cancers such as non-small cell lung cancer. Hence, targeting this protein is essential for improving drug design and preventing adverse drug-drug interactions. The aim of the study was to examine chemotherapeutic drug binding to MDR1 and the interactions therein. We have used Schrödinger suite 2014, to perform homology modelling of human MDR1 based on Mouse MDR1, followed by Induced Fit Docking with Paclitaxel, Docetaxel, Gemcitabine, Carboplatin and Cisplatin drugs...
April 2015: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/25661113/a-systematic-review-of-the-clinical-effectiveness-of-first-line-chemotherapy-for-adult-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer
#8
REVIEW
Gerlinde Pilkington, Angela Boland, Tamara Brown, James Oyee, Adrian Bagust, Rumona Dickson
Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellence (NICE) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). A systematic search of MEDLINE, EMBASE and the Cochrane Library for randomised controlled trials (RCTs) published from 2001 to 2010 was carried out. Relative treatment effects for overall survival (OS) and progression-free survival (PFS) were estimated using standard meta-analysis and mixed treatment comparison methodology...
April 2015: Thorax
https://www.readbyqxmd.com/read/25495098/clinical-effectiveness-and-clinical-toxicity-associated-with-platinum-based-doublets-in-the-first-line-setting-for-advanced-non-squamous-non-small-cell-lung-cancer-in-chinese-patients-a-retrospective-cohort-study
#9
Yan Wang, Jianhua Chen, Shengqi Wu, Chenping Hu, Xiaoling Li, Yuqin Wang, Yicheng Yang, Narayan Rajan, Yun Chen, Yi Chen, Zhuanzhuan Luo, Wendong Chen
BACKGROUND: Real-world evidence lacks for clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer (advNS-NSCLC) in Chinese patients. METHODS: Patients receiving first-line chemotherapy for advNS-NSCLC in four Chinese tertiary care hospitals from 2007 to 2012 were retrospectively identified for chart review. Propensity score methods created best matched pairs for platinum/pemetrexed versus other platinum-based doublets for head-to-head comparisons of early treatment discontinuation (completed treatment cycles <4), treatment failure (progressive disease or early treatment discontinuation), and adverse events (AE)...
2014: BMC Cancer
https://www.readbyqxmd.com/read/25019058/treatment-paradigms-for-patients-with-metastatic-non-small-cell-lung-cancer-squamous-lung-cancer-first-second-and-third-line
#10
REVIEW
Abdulaziz Al-Farsi, Peter Michael Ellis
Historically, the treatment algorithm applied to non-small cell lung cancer (NSCLC) was the same for all histologic subtypes. However, recent advances in our understanding of the molecular profiles of squamous and non-squamous NSCLC have changed this perspective. Histologic subtype and the presence of specific molecular abnormalities have predictive value for response to and toxicity from therapy, as well as overall survival. For patients with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended as first-line therapy...
2014: Frontiers in Oncology
https://www.readbyqxmd.com/read/24762685/-efficacies-and-toxicities-of-different-platinum-based-combination-chemotherapies-for-patients-with-advanced-non-small-cell-lung-cancer
#11
COMPARATIVE STUDY
Juan Liu, Fuyun Ji, Jin Li, Bin Wang, Guoming Wu
OBJECTIVE: To explore the efficacies and toxicities of different platinum-based combination chemotherapeutic regiments for patients with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 239 advanced NSCLC from January 2011 to December 2012 were reviewed in Xinqiao Hospital. The chemotherapeutic efficacies and adverse effects in the first-line treatment of advanced NSCLC by paclitaxel plus platinum (paclitaxel group, n = 113), gemcitabine plus platinum (gemcitabine group, n = 72) and docetaxel plus platinum (docetaxel group, n = 54) regiments were retrospectively analyzed and compared...
March 4, 2014: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/24682465/randomized-phase-ii-trial-comparing-carboplatin-plus-weekly-paclitaxel-and-docetaxel-alone-in-elderly-patients-with-advanced-non-small-cell-lung-cancer-north-japan-lung-cancer-group-trial-0801
#12
RANDOMIZED CONTROLLED TRIAL
Makoto Maemondo, Akira Inoue, Shunichi Sugawara, Toshiyuki Harada, Yuji Minegishi, Kazuhiro Usui, Koji Miwa, Naoto Morikawa, Mariko Kambe, Kenji Ube, Kana Watanabe, Osamu Ishimoto, Tomohiro Sakakibara, Akihiko Gemma, Toshihiro Nukiwa
BACKGROUND: Standard first-line chemotherapy for elderly non-small cell lung cancer (NSCLC) patients has been monotherapy with vinorelbine or gemcitabine. Docetaxel has also been considered as an alternative option for the elderly population in Japan. We have previously demonstrated the high efficacy of carboplatin plus weekly paclitaxel for elderly NSCLC patients. Consequently, we conducted a randomized phase II study to select the proper regimen for a future phase III trial. METHODS: Eligible patients were aged 70 years or older with newly diagnosed advanced NSCLC...
April 2014: Oncologist
https://www.readbyqxmd.com/read/24137188/decreased-levels-of-serum-cytokeratin-19-fragment-cyfra-21-1-predict-objective-response-to-chemotherapy-in-patients-with-non-small-cell-lung-cancer
#13
Li Pang, Jing Wang, Yanwen Jiang, Liangan Chen
Diagnostic tools capable of predicting early responses to chemotherapy are required to improve the individual management of cancer patients. The present study aimed to evaluate the prognostic significance of the serum tumor markers CYFRA 21-1, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), carbohydrate antigen (CA) 125, and CA 19-9 for predicting responses to different chemotherapy regimens in patients with non-small cell lung cancer (NSCLC). A total of 276 patients with postoperative stage I-IV NSCLC were retrospectively reviewed...
August 2013: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/24091849/a-phase-iii-concurrent-chemoradiotherapy-trial-with-cisplatin-and-paclitaxel-or-docetaxel-or-gemcitabine-in-unresectable-non-small-cell-lung-cancer-kaslc-0401
#14
In-Jae Oh, Kyu-Sik Kim, Young-Chul Kim, Hee-Jung Ban, Yong-Soo Kwon, Yu-Il Kim, Sung-Chul Lim, Woong-Ki Chung, Taek-Keun Nam, Joo-Young Song, Mee-Sun Yoon, Sung-Ja Ahn
PURPOSE: Concurrent chemoradiotherapy (CCRT) is recommended for the management of patients with unresectable non-small cell lung cancer (NSCLC). This prospective study aimed to compare the efficacy of concurrently delivered cisplatin doublets with paclitaxel, or docetaxel, or gemcitabine. METHODS: The main eligibility criteria consisted of previously untreated stage IIIB NSCLC. The subjects were randomized into three arms: paclitaxel 45 mg/m(2)/week (TP), docetaxel 20 mg/m(2)/week (DP), and gemcitabine 350 mg/m(2)/week (GP) in addition to cisplatin 20 mg/m(2)/week...
December 2013: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/24055492/combined-epidermal-growth-factor-receptor-egfr-tyrosine-kinase-inhibitor-and-chemotherapy-in-non-small-cell-lung-cancer-chemo-refractoriness-of-cells-harboring-sensitizing-egfr-mutations-in-the-presence-of-gefitinib
#15
Chun-Ming Tsai, Jen-Ting Chen, Chao-Hua Chiu, Chun-Liang Lai, Shih-Yin Hsiao, Kuo-Ting Chang
BACKGROUND: Combined epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) with chemotherapy is believed to be more effective in treating non-small-cell lung cancer (NSCLC) with sensitizing-EGFR mutation (SEM). This hypothesis failed to be realized clinically and needs to be examined in vitro. MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines...
November 2013: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/23996521/targeted-therapies-for-locally-advanced-or-metastatic-squamous-cell-carcinoma-of-the-lung
#16
Thomas E Stinchcombe
Most patients with squamous cell carcinoma (SCC) present with advanced or metastatic disease at the time of diagnosis. Given the low prevalence of oncogenic driver mutations in SCC, I do not routinely perform molecular testing. The times that I perform molecular testing in SCC are for patients with SCC and a light or never smoking history, adenosquamous histology, or when the histological diagnosis is not definitive. For patients with a good performance status and adequate organ function, a platinum doublet is the standard therapy, and I generally use carboplatin and gemcitabine or carboplatin and paclitaxel...
December 2013: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/23961854/-contemporary-trends-of-the-adjutant-chemotherapy-in-non-small-cell-lung-cancer
#17
REVIEW
V Kolek
BACKGROUND: Adjuvant chemotherapy became a standard of treatment in completely resected non-small cell lung cancer (NSCLC) based on results of big trials meta-analyses, which proved its influence on the decrease of relative mortality risk and absolute improvement of survival. Adjuvant chemotherapy is routinely used according to tumor stage evaluation, performance status (PS) and age of the patients. It is indicated in stage II and IIIA of NSCLC- in frame of clinical studies also in stage IB, in PS 0-1 and in patients under 75 years...
2013: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/23886301/clinical-effectiveness-and-cost-effectiveness-of-first-line-chemotherapy-for-adult-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-a-systematic-review-and-economic-evaluation
#18
REVIEW
T Brown, G Pilkington, A Bagust, A Boland, J Oyee, C Tudur-Smith, M Blundell, M Lai, C Martin Saborido, J Greenhalgh, Y Dundar, R Dickson
BACKGROUND: The National Institute for Health and Care Excellence (NICE) has issued multiple guidance for the first-line management of patients with lung cancer and recommends different combinations of chemotherapy treatments. This review provides a synthesis of clinical effectiveness and cost-effectiveness evidence supporting current guidance. OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of first-line chemotherapy currently licensed in Europe and recommended by NICE, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)...
July 2013: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/23728094/-analysis-of-the-risk-factors-for-severe-neutropenia-in-advanced-non-small-cell-lung-cancer-after-the-first-course-of-chemotherapy-with-third-generation-agents
#19
Midori Shibuya, Mari Kogo, Tatsuya Kurihara, Yusuke Shikama, Hiroaki Nakajima, Keiichiro Yoneyama, Yuji Kiuchi
  We retrospectively evaluated clinical data before therapy to determine the risk factors for severe neutropenia in advanced non-small-cell lung cancer (NSCLC) patients treated with third-generation agents. We analyzed 100 patients who received such agents (paclitaxel, docetaxel, gemcitabine, irinotecan, or vinorelbine) for advanced NSCLC. The endpoint of the survey was the occurrence of severe neutropenia (grade 4). Risk factors significantly related to severe neutropenia were identified using logistic regression analysis...
2013: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/23611404/does-histology-predict-survival-of-advanced-non-small-cell-lung-cancer-patients-treated-with-platin-based-chemotherapy-an-analysis-of-the-eastern-cooperative-oncology-group-study-e1594
#20
RANDOMIZED CONTROLLED TRIAL
Tien Hoang, Suzanne E Dahlberg, Joan H Schiller, David H Johnson
INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel...
July 2013: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
keyword
keyword
43174
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"